Shots: Tusk to get an upfront $81.2M with contingent payments up to $678.9M (€ 585M) based on certain milestones Roche plans to continue the development of novel Ab developed by Tusk for depleting regulatory T-cells. The program is expected to hit the clinics by Q4’19 for cancer patients Tusk’s Spinout Black Belt Therapeutics, will hold […]Read More
Tags : Tusk Therapeutic
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US